Gunderson Dettmer represented Lyndra Therapeutics, a developer of orally administered steady-state release pill, when it raised $55M in a Series B financing. The round of funding was led by Polaris Partners, with new investors HOPU Investments, Gilead Sciences, Invus, the Bill & Melinda Gates Foundation and Orient Life.

At the time of announcing Amy Schulman, co-founder and CEO of Lyndra Therapteutics, said in the press release, “The diversity and caliber of our investors, including those who joined this round, speaks to the importance of addressing unmet therapeutic need. I am proud of the speed with which the Lyndra team has moved from demonstrating feasibility to the clinic, and now we are well positioned to initiate additional Phase I clinical trials and continue our progress toward Phase II clinical trials.”

The Gunderson Dettmer team was led by Tim Ehrlich with Vanessa Smith, Chris Sintetos and Joel Diamond.